| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Stroke. 2001;32:661.)
© 2001 American Heart Association, Inc.
Original Contribution |
Clinical Deterioration Following Improvement in the NINDS rt-PA Stroke Trial
From the Department of Neurology (J.C.G), University of Texas Medical School, Houston; Deparments of Biostatistics and Research Epidemiology (M.L.), Pharmacy Services (M.R.F.), and Neurology (K.M.A.W, S.R.L.), Henry Ford Health Science Center, Detroit, Mich; Department of Neurology (M.R.F.), Emory University Medical School, Atlanta, Ga; Department of Neurology (T.B.), University of Cincinnati School of Medicine, Cincinnati, Ohio; Department of Neurology (S.R.L.), Wayne State University School of Medicine, Detroit, Mich; and the Department of Neurosciences (P.D.L.), University of California, San Diego.
Correspondence to James Grotta, MD, Stroke Program, Department of Neurology, University of Texas Medical School, 6431 Fannin, Houston, Texas 77030. E-mail james.c.grotta{at}uth.tmc.edu
Background and Purpose—Little is known in regard to cerebral arterial reocclusion after successful thrombolysis. In the absence of arteriographic information, the National Institute of Neurological Disorders and Stroke (NINDS) rt-PA Stroke Trial investigators prospectively identified clinical deterioration following improvement (DFI) as a possible surrogate marker of cerebral arterial reocclusion after rt-PA–induced recanalization. Also, we identified any significant clinical deterioration (CD) even if not preceded by improvement. This observational analysis was designed to determine the incidence of DFI and CD in each treatment group, to identify baseline or posttreatment variables predictive of DFI or CD, and to determine any relationship between DFI, CD, and clinical outcome.
Methods—DFI was defined as any 2-point deterioration on the NIH Stroke Scale after an initial 2-point improvement after treatment. CD was defined as any 4-point worsening after treatment compared with baseline. All data were collected prospectively by investigators blinded to treatment allocation. A noncontrast brain CT was mandated when a 2-point deterioration occurred. All cases were validated by a central review committee.
Results—DFI was identified in 81 of the 624 patients (13%); 44 were treated with rt-PA and 37 were treated with placebo (P=0.48). DFI occurred more often in patients with a higher baseline NIH Stroke Scale score. CD within the first 24 hours occurred in 98 patients (16% of all patients); 43 were given rt-PA and 55 were given placebo (P=0.19). Baseline variables associated with CD included a less frequent use of prestroke aspirin and a higher incidence of early CT changes of edema or mass effect or dense middle cerebral artery sign. Patients with CD had higher rates of increased serum glucose and fibrin degradation products, and they also had higher rates of symptomatic intracranial hemorrhage and death. Patients who experienced either DFI or CD were less likely to have a 3-month favorable outcome.
Conclusions—We found no association between DFI, CD, and rt-PA treatment, and no clinical evidence to suggest reocclusion. Deterioration was strongly associated with stroke severity and poor outcome and was less frequent in patients whose stroke occurred while they were on aspirin.
Key Words: deterioration • reocclusion • stroke • thrombolysis
This article has been cited by other articles:
 |
|
 |
|
  O. Moldes, T. Sobrino, M. Millan, M. Castellanos, N. Perez de la Ossa, R. Leira, J. Serena, J. Vivancos, A. Davalos, and J. Castillo High Serum Levels of Endothelin-1 Predict Severe Cerebral Edema in Patients With Acute Ischemic Stroke Treated With t-PA Stroke, July 1, 2008; 39(7): 2006 - 2010. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Uyttenboogaart, M. W. Koch, K. Koopman, P. C. A. J. Vroomen, J. De Keyser, and G.-J. Luijckx Safety of Antiplatelet Therapy Prior to Intravenous Thrombolysis in Acute Ischemic Stroke Arch Neurol, May 1, 2008; 65(5): 607 - 611. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Millan, T. Sobrino, M. Castellanos, F. Nombela, J. F. Arenillas, E. Riva, I. Cristobo, M. M. Garcia, J. Vivancos, J. Serena, et al. Increased Body Iron Stores Are Associated With Poor Outcome After Thrombolytic Treatment in Acute Stroke Stroke, January 1, 2007; 38(1): 90 - 95. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Saqqur, C. A. Molina, A. Salam, M. Siddiqui, M. Ribo, K. Uchino, S. Calleja, Z. Garami, K. Khan, N. Akhtar, et al. Clinical Deterioration After Intravenous Recombinant Tissue Plasminogen Activator Treatment: A Multicenter Transcranial Doppler Study Stroke, January 1, 2007; 38(1): 69 - 74. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Rajajee, C. Kidwell, S. Starkman, B. Ovbiagele, J. R. Alger, P. Villablanca, F. Vinuela, G. Duckwiler, R. Jahan, A. Fredieu, et al. Early MRI and outcomes of untreated patients with mild or improving ischemic stroke. Neurology, September 26, 2006; 67(6): 980 - 984. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Kwan and P. Hand Early neurological deterioration in acute stroke: clinical characteristics and impact on outcome QJM, September 1, 2006; 99(9): 625 - 633. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Tanne, R. F. Macko, Y. Lin, B. C. Tilley, S. R. Levine, and for the NINDS rtPA Stroke Study Group Hemostatic Activation and Outcome After Recombinant Tissue Plasminogen Activator Therapy for Acute Ischemic Stroke Stroke, July 1, 2006; 37(7): 1798 - 1804. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W.S. Smith and for the Multi MERCI Investigators Safety of Mechanical Thrombectomy and Intravenous Tissue Plasminogen Activator in Acute Ischemic Stroke. Results of the Multi Mechanical Embolus Removal in Cerebral Ischemia (MERCI) Trial, Part I AJNR Am. J. Neuroradiol., June 1, 2006; 27(6): 1177 - 1182. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. E. Smith, A. R. Abdullah, I. Petkovska, E. Rosenthal, W. J. Koroshetz, and L. H. Schwamm Poor Outcomes in Patients Who Do Not Receive Intravenous Tissue Plasminogen Activator Because of Mild or Improving Ischemic Stroke Stroke, November 1, 2005; 36(11): 2497 - 2499. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Rubiera, J. Alvarez-Sabin, M. Ribo, J. Montaner, E. Santamarina, J. F. Arenillas, R. Huertas, P. Delgado, F. Purroy, and C. A. Molina Predictors of Early Arterial Reocclusion After Tissue Plasminogen Activator-Induced Recanalization in Acute Ischemic Stroke Stroke, July 1, 2005; 36(7): 1452 - 1456. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Saposnik, B. Young, B. Silver, S. Di Legge, F. Webster, V. Beletsky, V. Jain, Y. Nilanont, and V. Hachinski Lack of Improvement in Patients With Acute Stroke After Treatment With Thrombolytic Therapy: Predictors and Association With Outcome JAMA, October 20, 2004; 292(15): 1839 - 1844. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Aiyagari, A. Gujjar, A. R. Zazulia, and M. N. Diringer Hourly Blood Pressure Monitoring After Intravenous Tissue Plasminogen Activator for Ischemic Stroke: Does Everyone Need It? Stroke, October 1, 2004; 35(10): 2326 - 2330. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. J. Coull and P. M. Rothwell Underestimation of the Early Risk of Recurrent Stroke: Evidence of the Need for a Standard Definition Stroke, August 1, 2004; 35(8): 1925 - 1929. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Barber, P. Langhorne, A. Rumley, G. D.O. Lowe, and D. J. Stott Hemostatic Function and Progressing Ischemic Stroke: D-dimer Predicts Early Clinical Progression Stroke, June 1, 2004; 35(6): 1421 - 1425. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. E. Kasner Editorial Comment--More Than One Way to Lyse a Clot Stroke, April 1, 2004; 35(4): 911 - 912. [Full Text] [PDF]
|
|
|
|
|
|
A. I. Qureshi, A. M. Siddiqui, S. H. Kim, R. A. Hanel, A. R. Xavier, J. F. Kirmani, M. F. K. Suri, A. S. Boulos, and L. N. Hopkins Reocclusion of Recanalized Arteries during Intra-arterial Thrombolysis for Acute Ischemic Stroke AJNR Am. J. Neuroradiol., February 1, 2004; 25(2): 322 - 328. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. C. Johnston and J. D. Easton Are Patients With Acutely Recovered Cerebral Ischemia More Unstable? Stroke, October 1, 2003; 34(10): 2446 - 2450. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. C. Johnston Transient Ischemic Attack N. Engl. J. Med., November 21, 2002; 347(21): 1687 - 1692. [Full Text] [PDF]
|
|
|
|
|
|
A. V. Alexandrov and J. C. Grotta Arterial reocclusion in stroke patients treated with intravenous tissue plasminogen activator Neurology, September 24, 2002; 59(6): 862 - 867. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Castellanos, J. Castillo, M. M. Garcia, R. Leira, J. Serena, A. Chamorro, and A. Davalos Inflammation-Mediated Damage in Progressing Lacunar Infarctions: A Potential Therapeutic Target Stroke, April 1, 2002; 33(4): 982 - 987. [Abstract] [Full Text] [PDF]
|
|